Screening for type 2 diabetes and prediabetes - Methodological concerns and feasibility in Hungary;A 2-es típusú diabetes és eloállapotainak szurése - Módszertani megfontolások, hazai lehetoségek

Orvosi Hetilap

Volumn 151, Issue 17, 2010, Pages 683-690

  Jermendy, György ^a   Hidvégi, Tibor ^a   Vándorfi, Gyozo ^a   Winkler, Gábor ^b  

^a Belgyógyászati Osztály ^*  (Hungary)

^b ST JOHN'S HOSPITAL   (Hungary)

Author keywords

FINDRISC questionnaire; Glucose intolerance; Prediabetes; Primary prevention; Screening; Type 2 diabetes

Indexed keywords

GLUCOSE;

DIABETIC PATIENT; FEASIBILITY STUDY; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; HUNGARY; IMPAIRED GLUCOSE TOLERANCE; METHODOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PREVALENCE; PRIMARY PREVENTION; QUESTIONNAIRE; REVIEW; RISK ASSESSMENT; SCREENING;

DIABETES MELLITUS, TYPE 2; FEASIBILITY STUDIES; GLUCOSE TOLERANCE TEST; HUMANS; HUNGARY; MASS SCREENING; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS;

EID: 77951200651     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2010.28818     Document Type: Review

References (50)

1. Jermendy Gy.: A praediabetes klinikai jelent?sege. Magyar Belorv. Arch., 2009, 62, 435-444.
2. Nadas J., Jermendy Gy.: A metabolikus szindromatol a kardiometabolikus kockazat fogalmaig. Orv. Hetil., 2009, 150, 821-829.
3. Wilson, J. M. G., Jungner, G.: Principles and practice of screening for disease. World Health Organization Public Health Papers No. 34. 1968. http://whqlibdoc.who.int/php/WHO-PHP- 34.pdf, letoltes: 2010. jan. 3.
4. Jermendy Gy.: A 2-es tipusu diabetes vilagmereti terjedesenek okai es kovetkezmenyei. LAM, 2006, 16, 105-113.
5. Zimmet, P., Alberti, K. G. M. M., Shaw, J.: Global and societal implications of diabetes epidemic. Nature, 2001, 414, 782-787.
6. King, H., Aubert, R. E., Herman, W. H.: Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care, 1998, 21, 1414-1431.
7. Wild, S., Roglic, G., Green, A. es mtsai: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care, 2004, 27, 1047-1053. (Pubitemid 38579764)
8. IDF Diabetes Atlas (fourth edition), 2009. International Diabetes Federation, Brussels. www.eatlas.idf.org, letoltes: 2010. januar 3.
9. Narayan, K. M., Boyle, J. P., Thompson, T. J. es mtsai: Lifetime risk for diabetes mellitus in the United States. JAMA, 2003, 290, 1884-1890.
10. Milicevic, Z., Raz, I., Beattie, S. D. es mtsai: Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia. Diabetes Care, 2008, 31, S155-S160.
11. A diabetes mellitus korismezese, a cukorbetegek kezelese es gondozasa feln?ttkorban. A Magyar Diabetes Tarsasag szakmai iranyelve, 2009 (szerk.: Jermendy Gy., irta: Ger? L., Hidvegi T., Jermendy Gy., Kempler P., Winkler G.). Diabetologia Hungarica, 2009, 17, 5-67.
12. Harris, M. I., Klein, R., Welborn, T. A. es mtsa: Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care, 1992, 15, 815-819.
13. U. K. Prospective Diabetes Study Group: U. K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes, 1995, 44, 1249-1258.
14. Tabak, A. G., Jokela, M., Akbaraly, T. N. es mtsai: Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet, 2009, 373, 2215-2221.
15. World Health Organization: Defi nition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. World Health Organization, Geneva, 2006.
16. Magyar Diabetes Tarsasag Metabolikus Munkacsoportja (Halmos T., Hidvegi T., Jermendy Gy., Kaplar M., Koranyi L., Pados Gy., Paragh Gy., Zajkas G.): A metabolikus szindroma defi nicioja, diag nosztikai kriteriumrendszere es sz?rese. Orv. Hetil., 2002, 143, 785-788.
17. Goth L.: A hemoglobin-A1c-meghatarozas analitikai problemai es az eredmenykozles gondjai. Orv. Hetil., 2009, 150, 747-751.
18. American Diabetes Association: Standards of medical care in diabetes - 2010. Diabetes Care, 2010 (Position Statement). 33, S11-S60.
19. Borch-Johnsen, K., Colagiuri, S.: Diagnosing diabetes - time for a change? Diabetologia, 2009, 52, 2247-2250.
20. Lindstrom, J., Tuomilehto, J.: The diabetes risk score. A practical tool to predict diabetes risk. Diabetes Care, 2003, 26, 725-731.
21. Baan, C. A., Ruige, J. B., Stolk, R. P. es mtsai: Performance of a predictive model to identify undiagnosed diabetes in a health care setting. Diabetes Care, 1999, 22, 213-219.
22. Balkau, B., Lange, C., Fezeu, L. es mtsai: Predicting diabetes: clinical, biological, and genetic approaches: data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care, 2008, 31, 2056-2061.
23. Glumer, C., Carstensen, B., Sandbaek, A. es mtsai: A Danish diabetes risk score for targeted screening: the Inter99 study. Diabetes Care, 2004, 27, 727-733.
24. Griffi n, S. J., Little, P. S., Hales, C. N. es mtsai: Diabetes risk score: towards earlier detection of type 2 diabetes in general practice. Diabetes Metab. Res. Rev., 2000, 16, 164-171.
25. Schmidt, M. I., Duncan, B. B., Bang, H. es mtsai: The Atherosclerosis Risk in Communities Investigators: identifying individuals at high risk for diabetes: the Atherosclerosis Risk in Communities Study. Diabetes Care, 2005, 28, 2013-2018.
26. Kahn, H. S., Cheng, Y. J., Thompson, T. J. es mtsai: Two riskscoring systems for predicting incident diabetes mellitus in U.S. adults age 45 to 64 years. Ann. Intern. Med., 2009, 150, 741-751.
27. Schulze, M. B., Hoffmann, K., Boeing, H. es mtsai: An accurate risk score based on anthropometric, dietary, and lifestyle factors to predict the development of type 2 diabetes. Diabetes Care, 2007, 30, 510-515. (Pubitemid 46354326)
28. Al-Lawati, J. A., Tuomilehto, J.: Diabetes risk score in Oman: a tool to identify prevalent type 2 diabetes among Arabs of the Middle East. Diabetes Res. Clin. Pract., 2004, 77, 438-444.
29. Ramachandran, A., Snehalatha, C., Vijay, V. es mtsai: Derivation and validation of diabetes risk score for urban Asian Indians. Diabetes Res. Clin. Pract., 2005, 70, 63-70.
30. Aekplakorn, W., Bunnag, P., Woodward, M. es mtsai: A risk score for predicting incident diabetes in the Thai population. Diabetes Care, 2006, 29, 1872-1877.
31. Kolberg, J. A., Jorgensen, T., Gerwien, R. W. es mtsai: Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort. Diabetes Care, 2009, 32, 1207-1212.
32. Hippisley-Cox, J., Coupland, C., Robson, J. es mtsai: Predicting risk of type 2 diabetes in England and Wales: prospective derivation and validation of QDScore. Br. Med. J., 2009, 338, b880.
33. Schwarz, P. E. H., Li, J, Lindstrom, J. es mtsa: Tools for predicting the risk of type 2 diabetes in daily practice. Horm. Metab. Res., 2009, 41, 86-97.
34. Schwarz, P. E., Li, J., Reimann, M. es mtsai: The Finnish Diabetes Risk Score is associated with insulin resistance and progression towards type 2 diabetes. J. Clin. Endocrinol. Metab., 2009, 94, 920-926.
35. Silventoinen, K., Pankow, J., Lindstrom, J. es mtsai: The validity of the Finnish Diabetes Risk Score for the prediction of the incidence of coronary heart disease and stroke, and total mortality. Eur. J. Cardiovasc. Prev. Rehabil., 2005, 12, 451-458.
36. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group: Intensive treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med., 2005, 353, 2643-2653.
37. Holman, R. R., Paul, S. K., Bethel, M. A. es mtsai: 10-year followup of intensive glucose control in type 2 diabetes. N. Engl. J. Med., 2008, 359, 1577-1589.
38. CDC Diabetes Cost-Effectiveness Study Group: The cost-effectiveness of screening for type 2 diabetes. JAMA, 1998, 280, 1757-1763.
39. Gillies, C. L., Lambert, P. C., Abrams, K. R. es mtsai: Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. Br. Med. J., 2008, 336, 1180-1185.
40. Jermendy Gy., Nadas J., Szigethy E. es mtsai: A cukorbetegseg es az emelkedett ehomi vercukor prevalenciaja a hazai felnitt koru (20-69 eves) lakossag koreben: reprezentativ keresztmetszeti szir-vizsgalat eredmenyei. Magyar Belorv. Arch., 2008, 61, 203-207.
41. Jermendy, G., Nadas, J., Szigethy, E. es mtsai: Prevalence rate of diabetes mellitus and impaired fasting glycaemia in Hungary - results from a cross-sectional study in nationally representative sample of people aged 20-69 years. Croat. Med. Y. In press, 2010.
42. Winkler G., Hidvegi T., Vandorfi Gy. es mtsa: Kockazatalapu diabetesszures felnottek koreben: az elsohazai vizsgalat eredmenyei. Orv. Hetil., 2010, 151, 691-696.
43. Jermendy, Gy.: Can type 2 diabetes mellitus be considered preventable? Diab. Res. Clin. Pract., 2005, 68, S73-S81.
44. Chiasson, J. L., Josse, R. G., Gomis, R. es mtsai for the STOPNIDDM Trial Research Group: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. The STOP-NIDDM Trial. JAMA, 2003, 290, 486-494.
45. Lindstrom, J., Ilanne-Parikka, P., Peltonen, M. es mtsai: Sustained reduction in the incidence of type 2 diabetes by lifestyle-intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet, 2006, 368, 1673-1679.
46. Uusitupa, M., Peltonen, M., Lindstrom, J. es mtsai: Ten-year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study - secondary analysis of the randomized trial. PLoS ONE 2009, 4, e5656. doi:10.1371/journal.pone.0005656
47. Gerstein, H., Yusuf, S., Riddle, M. C. es mtsai: Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am. Heart J., 2008, 155, 26-32.
48. Jermendy, Gy.: Late effect of treatment for reducing cardiovascular risk - a hypothesis on cardiometabolic therapeutic memory. Med. Hypotheses, 2009, 73, 73-79.
49. Alberti, K. G. M. M., Zimmet, P., Shaw, J.: International Diabetes Federation: a consensus on type 2 diabetes prevention. Diabet. Med., 2007, 24, 451-463. (Pubitemid 46669328)
50. Sheehy, A. M., Coursin, D. B., Baggay, R. A.: Back to Wilson and Jungner: 10 good reasons to screen for type 2 diabetes mellitus. Mayo Clin. Proc., 2009, 84, 38-42.